Photodynamic therapy for cutaneous squamous cell carcinoma in situ: Impact of anatomic location, tumor diameter, and incubation time on effectiveness - 14/04/20

Abstract |
Background |
Photodynamic therapy (PDT) has been reported as a treatment for cutaneous squamous cell carcinoma in situ (SCCis), but only limited data are available on the effectiveness of PDT with aminolevulinic acid (ALA-PDT).
Objective |
To review the outcomes of SCCis treated with ALA-PDT and examine factors associated with response.
Methods |
A retrospective review identified 58 patients with 68 primary SCCis lesions treated with ALA-PDT and blue light illumination. Patient demographics, lesion features, treatment details, clinical response, and subsequent recurrence were extracted from medical record reviews.
Results |
On completion of PDT the initial complete response rate was 77.9% and was not associated with the number of PDT treatments. On multivariate analysis factors associated with response were location on the face, tumor diameter <2 cm, and longer ALA incubation time. Lesions treated with a maximum incubation time of <3 hours had a 53.3% response compared with 84.9% for longer incubation. Subsequent recurrence of SCCis was noted in 7 of 53 cases (13.2%) at a median time of 11.7 months.
Limitations |
This was a retrospective study performed at a single institution without systematic follow-up.
Conclusions |
ALA-PDT may be an effective treatment for selected cases of SCCis. Effectiveness is impacted by anatomic location, tumor diameter, and ALA incubation time.
Il testo completo di questo articolo è disponibile in PDF.Key words : aminolevulinic acid, Bowen disease, humans, photodynamic therapy, retrospective studies, skin neoplasms, squamous cell carcinoma in situ, treatment outcome
Abbreviations used : ALA, ALA-PDT, CR, PDT, SCCis
Mappa
| Funding sources: Supported by a Career Development Award from the Dermatology Foundation (Dr Christensen). |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by the Yale Institutional Review Board (IRB number 2000024076). |
|
| Reprints not available from the authors. |
Vol 82 - N° 5
P. 1124-1130 - maggio 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
